Clinical Diagnostics Market: as immunodiagnostic and molecular platform base business sustains high single-digit organic growth independent of COVID-19 testing revenue normalisation, China healthcare pricing reform creates a multi-year structural headwind for cardiac and clinical chemistry test portfolios across the Asia-Pacific region, so instrument capital spending caution constrains new platform placements, and recurring reagent and consumable volume sustains global IVD revenue growth at a more moderate pace than pre-pandemic replacement cycle projections implied.

The global clinical diagnostics market size was USD 92.40 Billion in 2025 and is expected to register a revenue CAGR of 6.1% during the forecast period. Market revenue growth is driven by factors such as immunodiagnostic and molecular platform base business sustaining high single-digit organic growth, companion diagnostic integration with comprehensive genomic profiling, and as well as point-of-care molecular platform expansion across urgent care and pharmacy settings. The first driving factor is Roche Diagnostics Division base business growth of 8% at constant exchange rates in 2024, led by immunodiagnostic product demand and the January 2024 consolidation of Foundation Medicine comprehensive genomic profiling into the core Diagnostics Division, with Core Lab revenue reaching CHF 4.07 Billion in H1 2024 alone including 11% immunodiagnostics growth and 8% clinical chemistry growth, demonstrating that recurring reagent and consumable testing volume sustained double-digit growth in the company’s highest-revenue diagnostic product category. The second driving factor is Hologic’s confirmation of fiscal Q4 2024 organic Diagnostics revenue growth of 9.5% excluding COVID-19 revenues, with Molecular Diagnostics revenue specifically increasing 9.4% driven by higher sales of the BV CV/TV assay portfolio and non-COVID-19 respiratory assays as well as Biotheranostics laboratory testing services revenue, confirming durable underlying molecular testing volume growth at US clinical laboratories independent of pandemic-era testing revenue normalisation. The third driving factor is the structural expansion of point-of-care molecular and immunoassay platform testing through CLIA-waived instruments at urgent care, retail pharmacy, and physician office settings, supported by Danaher’s Cepheid GeneXpert platform accumulating broad infectious disease and sexual health assay menu approval and Abbott’s ID NOW platform achieving broad community care physician office deployment, creating testing infrastructure that generates recurring cartridge revenue per instrument placement without requiring laboratory professional staffing. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way companion diagnostic testing requirements mandated by FDA and international regulatory frameworks for targeted oncology therapeutics create a recurring co-dependent revenue stream between pharmaceutical approvals and diagnostic platform testing orders, which allows each new companion diagnostic indication approval to unlock a new recurring testing channel without requiring independent commercial marketing of the diagnostic product. Once a pharmaceutical companion diagnostic indication is approved requiring a specific IVD platform test for treatment eligibility determination, every patient enrolled in the approved drug therapy represents a mandated diagnostic test that must be ordered before or during treatment, so the commercial addressability of companion diagnostic testing compounds in direct proportion to the clinical adoption rate of each approved targeted oncology therapy. As a result, demand and revenue share are concentrating around diagnostic platforms with the broadest companion diagnostic indication portfolios and the deepest oncologist ordering relationships, and the forecast tilts toward these mandated diagnostic platforms rather than optional clinical utility testing. For instance, in November 2024, Roche completed the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specialising in donor-derived CAR-T cell therapies, one of more than a dozen strategic transactions that reshaped the clinical diagnostics competitive landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the sustained underlying clinical testing volume growth in immunodiagnostics and clinical chemistry, demonstrated by Roche’s Diagnostics Division base business excluding COVID-19 products growing 8% at constant exchange rates in 2024 across all regions, with Core Lab revenue growing 3% to CHF 4.07 Billion in H1 2024 with immunodiagnostics specifically up 11% and clinical chemistry up 8%. Immunodiagnostic testing works as the highest-revenue recurring product category because antibody-antigen binding assays enable the simultaneous detection and quantification of multiple cardiac biomarkers, thyroid hormones, infectious disease antigens and antibodies, and tumour markers in a single automated analyser run, providing the broadest test menu application coverage across hospital and reference laboratory testing channels of any single diagnostic platform technology. Effective January 1, 2024, Roche moved operational responsibility for the Foundation Medicine comprehensive genomic profiling business from Pharmaceuticals to the Diagnostics Division, consolidating companion diagnostic and comprehensive genomic profiling revenue within the company’s core diagnostics reporting and reflecting the strategic integration of molecular oncology diagnostics with traditional clinical laboratory testing. In November 2024, Roche completed the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specialising in donor-derived CAR-T cell therapies, expanding the company’s diagnostic and therapeutic integration capabilities in cellular oncology testing applications. The effect on the market is that the January 2024 Foundation Medicine consolidation creates a new revenue and margin disclosure benchmark for oncology companion diagnostic testing within the IVD sector, raising investor and commercial attention to the companion diagnostics category as a structural growth layer above the established immunoassay and clinical chemistry base. These are some of the key factors driving revenue growth of the market.

The second driver is the confirmed durable molecular diagnostics volume growth at US hospital and reference laboratory customers, demonstrated by Hologic’s fiscal Q4 2024 results showing organic Diagnostics revenue growth of 9.5% excluding COVID-19 revenues, with Molecular Diagnostics revenue specifically increasing 9.4% or 9.1% in constant currency. Molecular diagnostics testing works commercially because PCR and NAAT-based assays detect infectious disease pathogens with specificity and sensitivity levels that immunoassay serology testing cannot achieve for acute infection diagnosis, and the persistent population-level prevalence of bacterial vaginosis, sexually transmitted infections, and respiratory viral infections generates a high-volume recurring testing demand that is independent of pandemic-era testing volumes and seasonal respiratory fluctuation. Hologic’s full fiscal year 2024 results confirmed that the Aptima molecular diagnostic assay portfolio, used to detect chlamydia, gonorrhea, high-risk HPV, and other infectious agents, anchored the sustained Molecular Diagnostics growth trajectory across both hospital and reference laboratory customer channels, with BV CV/TV assay volume growing consistently throughout 2024. Biotheranostics laboratory testing services, which provide breast cancer tumour biology testing through Hologic’s commercial laboratory infrastructure, also contributed to Molecular Diagnostics growth, demonstrating that molecular testing volume growth is driven by multiple independent demand streams rather than a single assay category. The effect on the market is that near-double-digit organic molecular diagnostics growth at a major IVD company through fiscal 2024 despite the continued absence of COVID-19 testing volume confirms that the clinical diagnostics sector has successfully recalibrated its revenue base to sustainable underlying testing demand, which validates the 6.1% market CAGR forecast above the broader healthcare spending growth rate. These are some of the key factors driving revenue growth of the market.

Roche Diagnostics Division base business growth of 8% at constant exchange rates in 2024, with immunodiagnostics growing 11% and clinical chemistry growing 8%, demonstrates that recurring reagent and consumable testing volume sustains double-digit growth rates in the highest-revenue IVD product categories independent of new instrument capital placement cycles. The January 2024 consolidation of Foundation Medicine into the Diagnostics Division signals that companion diagnostic testing will become the structural growth driver above the established immunoassay and clinical chemistry base over the 2026 to 2035 forecast period.

The third driver is the structural expansion of CLIA-waived point-of-care molecular and immunoassay testing into non-laboratory clinical settings that were previously unable to offer molecular diagnostic testing due to the staffing and infrastructure requirements of conventional PCR platforms. Point-of-care molecular testing works commercially because CLIA-waived platforms like Cepheid GeneXpert and Abbott ID NOW can be operated by non-laboratory healthcare personnel at the point of patient care, delivering actionable infectious disease test results within 15 to 45 minutes, enabling same-visit diagnosis and treatment initiation that improves patient outcomes and physician satisfaction relative to laboratory send-out testing requiring 24 to 72 hours for results. Danaher’s Cepheid GeneXpert installed base has accumulated over 50,000 instrument placements globally, generating recurring GeneXpert cartridge revenue across an HIV viral load monitoring, tuberculosis diagnosis, and respiratory panel indication portfolio that is expanding through FDA clearances for additional sexual health and antimicrobial resistance applications. The February 2026 closing of the Becton Dickinson and Waters Corporation diagnostics and chromatography combination created a scaled IVD and mass spectrometry platform company with expanded clinical laboratory automation and toxicology testing capabilities, demonstrating continued large-scale consolidation at the IVD sector level. The effect on the market is that CLIA-waived point-of-care molecular platform expansion creates a new addressable testing revenue channel above the existing hospital and reference laboratory base without requiring traditional laboratory infrastructure, so each physician office or urgent care centre instrument placement adds durable recurring cartridge revenue from the care settings closest to underserved and rural patient populations. These are some of the key factors driving revenue growth of the market.

However, the clinical diagnostics market faces restraint from China healthcare pricing reform and its cascading effect on Asia-Pacific IVD revenue growth. Because Roche confirmed that pricing reform had a significant negative impact on Diagnostics Division sales in H1 2025, specifically targeting cardiac and clinical chemistry test reimbursement rates that represent the highest-volume recurring revenue product categories across the IVD sector, the reform creates a multi-year structural headwind for IVD manufacturers with substantial China hospital procurement exposure that cannot be offset through volume growth at current reformed test pricing levels. COVID-19 testing revenue normalisation is a second constraint, with Roche reporting a 73% constant-exchange-rate decline in COVID-19 test sales to CHF 0.2 Billion in 2024, requiring base business growth to substantially outpace this decline to sustain overall division-level expansion, and any resurgence of COVID-19 variant activity creating temporary testing volume spikes followed by renewed revenue comparison challenges. Conservative capital equipment spending is the third constraint, since the diagnostics and life sciences tools sector has experienced a broad pattern of constrained instrument capital placement across hospital and reference laboratory customers following pandemic-era over-investment, so new instrument platform launches by Roche, Abbott, Siemens Healthineers, and Beckman Coulter are competing for capital budget allocation against established installed base upgrade deferrals across their own customer bases. These factors substantially limit clinical diagnostics market growth over the forecast period.

Based on regional analysis, the clinical diagnostics market in North America accounted for largest revenue share in 2025. The United States drives the regional position through the concentrated presence of major reference laboratory networks including Quest Diagnostics and Laboratory Corporation of America, combined with Roche, Abbott, Hologic, and Becton Dickinson’s substantial US commercial diagnostics infrastructure and the world’s largest healthcare expenditure base supporting comprehensive clinical testing menu reimbursement. Hologic’s fiscal Q4 2024 organic Diagnostics revenue growth of 9.5% excluding COVID-19 revenues was substantially driven by US hospital and reference laboratory molecular diagnostics demand, reflecting the structural depth of the North American clinical diagnostics testing infrastructure anchored in the mandatory infectious disease, women’s health, and companion diagnostic testing menus deployed across all major US clinical laboratory networks. The concentration of the FDA companion diagnostic approval pathway, the largest clinical laboratory network reimbursement base, and five of the top ten global IVD company headquarters in North America also means that new clinical diagnostic test platforms achieve commercial scale in the United States first before achieving equivalent European or Asian market penetration.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Switzerland, Germany, and France represent significant national clinical diagnostics markets within Europe, anchored by Roche Diagnostics’ Basel, Switzerland global headquarters and the company’s deep European commercial infrastructure across hospital and reference laboratory customers. The ongoing Iran-US sanctions and associated Strait of Hormuz maritime disruption affect specialty reagent and antibody component supply chains for European immunoassay and molecular diagnostic manufacturers, increasing procurement costs for specialty reagent inputs that contribute to European diagnostic reagent list price stickiness in the 2026 to 2027 period while constraining the margin improvement that European IVD manufacturers would otherwise achieve from operating leverage on growing testing volumes. The CE-IVDR regulatory framework creates additional compliance cost requirements for IVD manufacturers selling in Europe that add regulatory and quality management investment above US FDA requirements.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, South Korea, and Australia represent the largest clinical diagnostics markets within the Asia Pacific region outside China, with well-developed national health insurance systems supporting comprehensive clinical laboratory test reimbursement. China’s healthcare pricing reform confirmed by Roche in H1 2025 as having a significant negative impact on Diagnostics Division cardiac and clinical chemistry test sales represents the primary near-term constraint on Asia-Pacific clinical diagnostics growth, creating a multi-year headwind for IVD manufacturers with substantial China hospital procurement exposure until reformed pricing reaches a new stable equilibrium. India represents the fastest-growing Asia Pacific clinical diagnostics national market outside China, with hospital diagnostic infrastructure investment and expanding private laboratory network development supporting immunoassay and molecular diagnostics volume growth that is not subject to the China pricing reform headwind.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national clinical diagnostics markets in the region, with private hospital laboratory networks and independent reference laboratory operators in major urban centres providing immunoassay and molecular diagnostics testing access. Public sector laboratory infrastructure in Latin America operates under constrained procurement budgets that limit access to premium IVD platforms, and the indirect effects of Iran-US sanctions on Latin American freight routes have maintained elevated import costs for specialty reagent components entering Brazilian and Mexican IVD distribution networks through 2026, contributing to diagnostic reagent pricing pressure in price-sensitive public sector laboratory procurement channels.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the United Arab Emirates represent the largest clinical diagnostics markets within the GCC, supported by substantial government investment in hospital diagnostic laboratory infrastructure and growing demand for advanced immunoassay, molecular, and companion diagnostic testing at private hospital networks serving large expatriate populations with international healthcare standards expectations. South Africa is the most established clinical diagnostics market on the African continent, anchored by private hospital group laboratory networks in Johannesburg and Cape Town, while Sub-Saharan Africa represents a largely underpenetrated addressable market where point-of-care infectious disease testing represents the primary IVD investment priority.